A Message from Dr. Nancy Mendenhall Over the past two years, we have been searching for funding opportunities to support another 5 years of follow-up for the COMPPARE cohorts to provide all participants with a minimum of 8 years of follow-up. This spring a new funding opportunity was…
Seven years ago, a routine physical for Dan McCarthy yielded an unexpected and unwelcome result: an elevated PSA and a recommendation for a biopsy. Dan and his wife Cindy O’Connell (shown right) couldn’t have been more shocked when the results were positive for prostate cancer. “There is no family history…
ProCure Proton Therapy Center opened its doors in Somerset NJ in March 2012, becoming the tri-state region’s first and longest-established proton therapy facility. Eight years later, in October 2020, the center marked another milestone: a prostate cancer patient became the 5,000th person treated with proton therapy at…
A Message from Dr. Nancy Mendenhall Since COMPPARE was launched in 2017, new information has emerged that suggests there may be other differences in outcomes between photon and proton radiation in prostate cancer. We would like to answer as many of these questions as…
By Bob Marckini Last month, a gentleman told us, sadly, that his father had died from prostate cancer. He then admitted he’d met with his primary care doctor only sporadically over the years and, despite this, didn’t even have regular PSA tests or DREs. Further, he skipped doctors’ visits completely…
Patient Accrual Closes, Participant Surveys are Collected, and Data Analysis Begins In 2017, a research team led by Nancy Mendenhall, M.D., medical director of the UF Health Proton Therapy Institute, was awarded a five-year, $11.9 million grant from the Patient-Centered Outcomes Research Institute (PCORI) to directly compare…
Dr. Nancy Mendenhall discusses COMPPARE with the MUSC radiation oncology team. The Medical University of South Carolina, Charleston (MUSC), founded in 1824, is South Carolina’s sole integrated academic health sciences center. Similarly, MUSC’s Hollings Cancer Center, one of 71 National Cancer Institute-designated cancer centers in the nation,…
A Message from Dr. Nancy Mendenhall I am excited to share with you that on October 31, 2022, COMPPARE closed enrollment with a total of 2,524 participants (1,024 photon patients and 1,500 proton patients; 900 pragmatic, 600 randomized)! Read Dr. Mendenhall’s message. Partner Site…
The COMPPARE Coordinating Center announced today that the study has enrolled its 1,000th photon prostate cancer patient to reach 67% of its photon cohort goal. COMPPARE Partner Site University of Maryland enrolled the 1,000th patient, followed closely by UNC REX Healthcare, Raleigh, NC, which…
A Message from Dr. Nancy Mendenhall As we near the completion of COMPPARE’s overall enrollment objective – a total of 3,000 patients – we are beginning to reflect and evaluate what we’ve learned thus far in creating and carrying out a large, multi-institutional pragmatic…
